The use of Immunotherapy in unresectable Hepatocellular Carcinoma (HCC)

Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based combinations, along with emerging therapies and the latest clinical data. Topics also include: • Efficacy and safety of IO and IO combinations in HCC• How to select between the two 1st-line IO-based treatment options based on clinical factors• Future treatment in unresectable HCC Clinical Takeaways• Two 1st-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape• Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies• Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen (single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up• IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary• In clinical practice, treatment choice should be individualised, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits   Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at [email protected]